ALK

Mutations in ALK are seen in about 3% of all cancers, and in 9% of skin cancers, 5% of colorectal cancers, and 3% of lung cancers. Point mutations in ALK are also common in neuroblastoma. Some specific ALK mutations predict sensitivity to ALK inhibitors, while others predict resistance.